DOCSLIB.ORG

Phosphoproteomic Analysis Identifies the Tumor Suppressor PDCD4 As a RSK Substrate Negatively Regulated by 14-3-3

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Phosphoproteomic Analysis Identifies the Tumor Suppressor PDCD4 As a RSK Substrate Negatively Regulated by 14-3-3 Phosphoproteomic analysis identifies the tumor suppressor PDCD4 as a RSK substrate negatively regulated by 14-3-3 Jacob A. Galana,b, Kathryn M. Geraghtyc, Geneviève Lavoiea, Evgeny Kanshina,d, Joseph Tcherkeziana,b, Viviane Calabresea,b, Grace R. Jeschkee, Benjamin E. Turke, Bryan A. Balliff, John Blenisc, Pierre Thibaulta,d, and Philippe P. Rouxa,b,1 aInstitute for Research in Immunology and Cancer, Montreal, QC, Canada H3C 3J7; bDepartment of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada H3C 3J7; cDepartment of Cell Biology, Harvard Medical School, Boston, MA 02115; dDepartment of Chemistry, Faculty of Arts and Science, Université de Montréal, Montreal, QC, Canada H3C 3J7; eDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT 06510; and fDepartment of Biology, University of Vermont, Burlington, VT 05405 Edited by Melanie H. Cobb, University of Texas Southwestern Medical Center, Dallas, TX, and approved June 13, 2014 (received for review April 9, 2014) The Ras/MAPK signaling cascade regulates various biological func- The 14-3-3 family of pSer/Thr-binding proteins dynamically reg- tions, including cell growth and proliferation. As such, this path- ulates the activity of various client proteins involved in diverse way is frequently deregulated in several types of cancer, including biological processes (11). In response to growth factors, 14-3-3 most cases of melanoma. RSK (p90 ribosomal S6 kinase) is a MAPK- proteins orchestrate a complex network of molecular interactions activated protein kinase required for melanoma growth and to achieve well-controlled physiological outputs, such as cell growth proliferation, but relatively little is known about its exact function and proliferation. Many 14-3-3-binding proteins contain sequences and the nature of its substrates. Herein, we used a quantitative that match its general consensus motif, which consists of RSXpS/ phosphoproteomics approach to define the signaling networks pTXP (12). Based on the requirement for an Arg residue at the −3 regulated by RSK in melanoma. To more accurately predict direct position, 14-3-3 client proteins are often phosphorylated by baso- phosphorylation substrates, we defined the RSK consensus phos- philic protein kinases, such as members of the AGC family. phorylation motif and found significant overlap with the binding Quantitative phosphoproteomics has emerged as a powerful consensus of 14-3-3 proteins. We thus characterized the phospho- tool in the elucidation of complex signaling networks. In this dependent 14-3-3 interactome in melanoma cells and found that study, we used quantitative liquid chromatography mass spec- a large proportion of 14-3-3 binding proteins are also potential trometry (LC-MS) to define the RSK phosphoproteome in mel- RSK substrates. Our results show that RSK phosphorylates the anoma cells. We characterized the primary sequence motif spec- tumor suppressor PDCD4 (programmed cell death protein 4) on two serine residues (Ser76 and Ser457) that regulate its subcellular ificity of RSK and observed significant overlap with the 14-3-3 localization and interaction with 14-3-3 proteins. We found that binding motif. Characterization of the 14-3-3 interactome in 14-3-3 binding promotes PDCD4 degradation, suggesting an melanoma cells resulted in the identification of a large number important role for RSK in the inactivation of PDCD4 in melanoma. of potential RSK substrates. We characterized the tumor sup- In addition to this tumor suppressor, our results suggest the in- pressor programmed cell death protein 4 (PDCD4) and found – volvement of RSK in a vast array of unexplored biological func- that RSK promotes its degradation in a 14-3-3 dependent manner. tions with relevance in oncogenesis. Together, these results cast insights on the diverse biological func- tions regulated by RSK in cancer cells. he Ras/MAPK pathway plays a key role in transducing ex- Ttracellular signals to intracellular targets involved in cell Significance growth and proliferation (reviewed in ref. 1). Inappropriate regulation of this pathway leads to a variety of diseases, including The RSK family is a group of Ser/Thr kinases that promotes cell cancer (2). In this pathway, the small GTPase Ras activates the growth and proliferation in response to the Ras/MAPK path- Raf isoforms, which are Ser/Thr kinases frequently mutated in way. Deregulated RSK activity has been associated with dif- human cancers (3). One prominent example is melanoma, which ferent disorders and diseases, such as cancer, but relatively little harbors activating B-Raf mutations (V600E) in a majority of is known regarding the contribution of RSK to tumorigenesis. cases (4). In turn, activated Raf phosphorylates and activates In this study, we describe, to our knowledge, the first global MEK1/2, which themselves phosphorylate and activate the quantitative phosphoproteomic screen to characterize RSK- MAPKs ERK1/2 (5). Once activated, ERK1/2 phosphorylate dependent signaling events in melanoma. Our results show that many substrates, including members of the p90 ribosomal S6 RSK negatively regulates the tumor suppressor PDCD4 by pro- kinase (RSK) family of proteins (6). Although the requirement moting its association to 14-3-3 proteins and subsequent pro- of ERK1/2 signaling in melanoma is well established, relatively teasomal degradation. These findings further implicate RSK as little is known regarding RSK signaling. a promising therapeutic target for the treatment of melanoma The RSK family is composed of four Ser/Thr kinases (RSK1–4) and suggest that RSK plays widespread biological functions that share 73–80% sequence identity and belong to the AGC downstream of the Ras/MAPK pathway. family of basophilic protein kinases (6). The RSK isoforms have Author contributions: J.A.G., K.M.G., G.L., E.K., J.T., V.C., G.R.J., B.E.T., B.A.B., J.B., P.T., and been shown to regulate a number of substrates involved in cell P.P.R. designed research; J.A.G., K.M.G., G.L., E.K., J.T., V.C., and G.R.J. performed re- growth and proliferation, and accordingly, inhibition of their ac- search; J.A.G., K.M.G., G.L., E.K., J.T., G.R.J., B.E.T., B.A.B., J.B., P.T., and P.P.R. analyzed tivity reduces the proliferation of several cancer cell lines (7, 8). data; and J.A.G. and P.P.R. wrote the paper. Consistent with this, RSK1 and RSK2 were shown to be over- The authors declare no conflict of interest. expressed in breast and prostate cancers (7, 8) and hyperactivated This article is a PNAS Direct Submission. in melanoma (9). Although RSK plays an important role in 1To whom correspondence should be addressed. Email: [email protected]. melanoma (10), relatively little is known about the substrates This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. it regulates. 1073/pnas.1405601111/-/DCSupplemental. E2918–E2927 | PNAS | Published online July 7, 2014 www.pnas.org/cgi/doi/10.1073/pnas.1405601111 Downloaded by guest on September 24, 2021 Results used an antibody that recognizes the consensus motif (RXXpS/T, PNAS PLUS A Proteomic Strategy for Characterizing the RSK-Dependent where X is any amino acid), which is phosphorylated by AGC Phosphoproteome. To characterize the RSK-dependent phospho- family kinases including RSK (13). We demonstrated that PMA proteome, we devised a comprehensive quantitative MS strategy treatment results in many immunoreactive bands that are se- using pharmacological inhibitors and RNAi (Fig. 1A). As bi- verely reduced when cells are pretreated with either MEK1/2 ological models, we used HEK293 cells treated with the phorbol (PD184352) or RSK (BI-D1870) inhibitors (Fig. 1B). Similarly, ester phorbol-12-myristate-13-acetate (PMA) to acutely stimu- we found that A375 melanoma cells have constitutively high late RSK activity, as well as A375 melanoma cells, which harbor levels of immunoreactive bands, which were also significantly the B-Raf V600E mutation and therefore have constitutively reduced by MEK1/2 or RSK inhibitors. We also depleted RSK1 high RSK activity (10). To optimize these cellular models, we and RSK2 by RNAi, which are the predominantly expressed BIOCHEMISTRY Fig. 1. Proteomic strategy for the characterization of the RSK-dependent phosphoproteome. (A) Schematic representation of the agonists and pharma- cological inhibitors used in this study. (B) HEK293 and A375 cells were serum-starved for 24 h before incubation with PD184352 (10 μM) or BI-D1870 (10 μM) for 30 min in HEK293 cells and 2 h in A375 cells, respectively. HEK293 cells were stimulated with PMA (50 ng/mL) for 30 min or left unstimulated. Protein lysates were resolved by SDS/PAGE and analyzed by immunoblotting with the indicated antibodies. (C) HEK293 and A375 cells were infected with lentiviral shRNA constructs targeted against a scrambled sequence (Scr) or RSK1/2. After selection, cells were serum-starved and stimulated with either PMA (50 ng/mL) or left unstimulated. Protein lysates were resolved by SDS-PAGE and analyzed by immunoblotting with the indicated antibodies. (D) Schematic representation of the different conditions analyzed using SILAC and LC-MS/MS. The relative abundance in phosphopeptides was compared between SILAC pairs, which comprised HEK293 and A375 cells treated with MEK1/2 (PD184352) or RSK (BI-D1870) inhibitors, or subjected to a nontarget or RSK1/2 shRNAs. Galan et al. PNAS | Published online July 7, 2014 | E2919 Downloaded by guest on September 24, 2021 isoforms in both cell types (10). Simultaneous knockdown of and heavy isotope-labeled cells were then combined and digested RSK1/2 resulted in a strong decrease in immunoreactive bands with trypsin and relative changes in protein abundances were compared with cells subjected to a control shRNA (Fig. 1C). measured using MS (Fig. 1D). Both RNAi and inhibitor treat- Together, these data validate our cellular models for further use ments did not globally perturb protein levels, as shown by the in a phosphoproteomic screen.
Load more

Recommended publications
  • Aberrant Modulation of Ribosomal Protein S6 Phosphorylation Confers Acquired Resistance to MAPK Pathway Inhibitors in BRAF-Mutant Melanoma
    www.nature.com/aps ARTICLE Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma Ming-zhao Gao1,2, Hong-bin Wang1,2, Xiang-ling Chen1,2, Wen-ting Cao1,LiFu1, Yun Li1, Hai-tian Quan1,2, Cheng-ying Xie1,2 and Li-guang Lou1,2 BRAF and MEK inhibitors have shown remarkable clinical efficacy in BRAF-mutant melanoma; however, most patients develop resistance, which limits the clinical benefit of these agents. In this study, we found that the human melanoma cell clones, A375-DR and A375-TR, with acquired resistance to BRAF inhibitor dabrafenib and MEK inhibitor trametinib, were cross resistant to other MAPK pathway inhibitors. In these resistant cells, phosphorylation of ribosomal protein S6 (rpS6) but not phosphorylation of ERK or p90 ribosomal S6 kinase (RSK) were unable to be inhibited by MAPK pathway inhibitors. Notably, knockdown of rpS6 in these cells effectively downregulated G1 phase-related proteins, including RB, cyclin D1, and CDK6, induced cell cycle arrest, and inhibited proliferation, suggesting that aberrant modulation of rpS6 phosphorylation contributed to the acquired resistance. Interestingly, RSK inhibitor had little effect on rpS6 phosphorylation and cell proliferation in resistant cells, whereas P70S6K inhibitor showed stronger inhibitory effects on rpS6 phosphorylation and cell proliferation in resistant cells than in parental cells. Thus regulation of rpS6 phosphorylation, which is predominantly mediated by BRAF/MEK/ERK/RSK signaling in parental cells, was switched to mTOR/ P70S6K signaling in resistant cells. Furthermore, mTOR inhibitors alone overcame acquired resistance and rescued the sensitivity of the resistant cells when combined with BRAF/MEK inhibitors.
    [Show full text]
  • Human Melanoma Cells Resistant to MAPK Inhibitors Can Be Effectively Targeted by Inhibition of the P90 Ribosomal S6 Kinase
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 22), pp: 35761-35775 Research Paper Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase Corinna Kosnopfel1, Tobias Sinnberg1, Birgit Sauer1, Heike Niessner1, Anja Schmitt2, Elena Makino1, Andrea Forschner1, Stephan Hailfinger2, Claus Garbe1, Birgit Schittek1 1Division of Dermatooncology, Department of Dermatology, University of Tübingen, Tübingen, Germany 2Interfaculty Institute of Biochemistry, University of Tübingen, Tübingen, Germany Correspondence to: Birgit Schittek, email: [email protected] Keywords: melanoma, MAPK inhibition, therapy resistance, p90 ribosomal S6 kinase, YB-1 Received: January 18, 2017 Accepted: March 06, 2017 Published: March 15, 2017 Copyright: Kosnopfel et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT The clinical availability of small molecule inhibitors specifically targeting mutated BRAF marked a significant breakthrough in melanoma therapy. Despite a dramatic anti-tumour activity and improved patient survival, rapidly emerging resistance, however, greatly limits the clinical benefit. The majority of the already described resistance mechanisms involve a reactivation of the MAPK signalling pathway. The p90 ribosomal S6 kinase (RSK), a downstream effector of the MAPK signalling cascade, has been reported to enhance survival of melanoma cells in response to chemotherapy. Here, we can show that RSK activity is significantly increased in human melanoma cells with acquired resistance to the BRAFV600E/K inhibitor vemurafenib. Interestingly, inhibition of RSK signalling markedly impairs the viability of vemurafenib resistant melanoma cells and is effective both in two-dimensional and in three-dimensional culture systems, especially in a chronic, long-term application.
    [Show full text]
  • The Role of the S6K2 Splice Isoform in Mtor/S6K Signalling and Cellular Functions
    The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions Olena Myronova A thesis submitted to the University College London in fulfilment with the requirements for the degree of Doctor of Philosophy London, November 2015 Research Department of Structural and Molecular Biology Division of Biosciences University College London Gower Street London, WC1E 6BT United Kingdom Ludwig Institute for Cancer Research 666 Third Avenue, 28th floor New York, N.Y. 10017 USA The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 1 Declaration I, Olena Myronova, declare that all the work presented in this thesis is the result of my own work. The work presented here does not constitute part of any other thesis. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. The work here in was carried out while I was a graduate research student at University College London, Research Department of Structural and Molecular Biology under the supervision of Professor Ivan Gout. Olena Myronova The role of the S6K2 splice isoform in mTOR/S6K signalling and cellular functions 2 Abstract Ribosomal S6 kinase (S6K) is a member of the AGC family of serine/threonine protein kinases and plays a key role in diverse cellular processes, including cell growth, survival and metabolism. Activation of S6K by growth factors, amino acids, energy levels and hypoxia is mediated by the mTOR and PI3K signalling pathways. Dysregulation of S6K activity has been implicated in a number of human pathologies, including cancer, diabetes, obesity and ageing.
    [Show full text]
  • Extracellular Receptor Kinase and Camp Response Element Binding Protein Activation in the Neonatal Rat Heart After Perinatal Cocaine Exposure
    0031-3998/04/5606-0947 PEDIATRIC RESEARCH Vol. 56, No. 6, 2004 Copyright © 2004 International Pediatric Research Foundation, Inc. Printed in U.S.A. Extracellular Receptor Kinase and cAMP Response Element Binding Protein Activation in the Neonatal Rat Heart after Perinatal Cocaine Exposure LENA S. SUN AND AARON QUAMINA Department of Anesthesiology [L.S.S., A.Q.] and Pediatrics [L.S.S.], College of Physicians & Surgeons, Columbia University, New York, NY 10032 ABSTRACT Prenatal exposure to cocaine has been shown to induce an and phospho-RSK. We assessed the interaction of RSK with increase in the myocardial expression and activation of the CREB or CREB-binding protein by performing co-immunopre- cAMP response binding protein (CREB), a transcriptional factor cipitation experiments. We found that perinatal cocaine exposure that has been shown to regulate gene expression. Several differ- increased both phospho-ERK and phospho-RSK expression, in- ent kinases, including protein kinase A, calcium calmodulin dicative of an increased activity of these two enzymes. Further- kinase II, and mitogen-activated protein kinase can induce phos- more, we demonstrated that phospho-RSK was immunoprecipi- phorylation of CREB at serine 133, a necessary step for CREB tated with CREB in all neonatal cardiac nuclei and that the activation. We examined whether the mitogen-activated protein greatest interaction was found in day 7 hearts after perinatal kinase–extracellular receptor kinase (ERK) pathway may be cocaine exposure. Our results thus illustrate that the ERK-RSK involved in mediating the serine 133 CREB phosphorylation in pathway was active in the postnatal rat heart at 1 and7dofage cardiac nuclei after perinatal cocaine exposure.
    [Show full text]
  • Role of Cyclin-Dependent Kinase 1 in Translational Regulation in the M-Phase
    cells Review Role of Cyclin-Dependent Kinase 1 in Translational Regulation in the M-Phase Jaroslav Kalous *, Denisa Jansová and Andrej Šušor Institute of Animal Physiology and Genetics, Academy of Sciences of the Czech Republic, Rumburska 89, 27721 Libechov, Czech Republic; [email protected] (D.J.); [email protected] (A.Š.) * Correspondence: [email protected] Received: 28 April 2020; Accepted: 24 June 2020; Published: 27 June 2020 Abstract: Cyclin dependent kinase 1 (CDK1) has been primarily identified as a key cell cycle regulator in both mitosis and meiosis. Recently, an extramitotic function of CDK1 emerged when evidence was found that CDK1 is involved in many cellular events that are essential for cell proliferation and survival. In this review we summarize the involvement of CDK1 in the initiation and elongation steps of protein synthesis in the cell. During its activation, CDK1 influences the initiation of protein synthesis, promotes the activity of specific translational initiation factors and affects the functioning of a subset of elongation factors. Our review provides insights into gene expression regulation during the transcriptionally silent M-phase and describes quantitative and qualitative translational changes based on the extramitotic role of the cell cycle master regulator CDK1 to optimize temporal synthesis of proteins to sustain the division-related processes: mitosis and cytokinesis. Keywords: CDK1; 4E-BP1; mTOR; mRNA; translation; M-phase 1. Introduction 1.1. Cyclin Dependent Kinase 1 (CDK1) Is a Subunit of the M Phase-Promoting Factor (MPF) CDK1, a serine/threonine kinase, is a catalytic subunit of the M phase-promoting factor (MPF) complex which is essential for cell cycle control during the G1-S and G2-M phase transitions of eukaryotic cells.
    [Show full text]
  • The P90 RSK Family Members: Common Functions and Isoform Specificity
    Published OnlineFirst August 22, 2013; DOI: 10.1158/0008-5472.CAN-12-4448 Cancer Review Research The p90 RSK Family Members: Common Functions and Isoform Specificity Romain Lara, Michael J. Seckl, and Olivier E. Pardo Abstract The p90 ribosomal S6 kinases (RSK) are implicated in various cellular processes, including cell proliferation, survival, migration, and invasion. In cancer, RSKs modulate cell transformation, tumorigenesis, and metastasis. Indeed, changes in the expression of RSK isoforms have been reported in several malignancies, including breast, prostate, and lung cancers. Four RSK isoforms have been identified in humans on the basis of their high degree of sequence homology. Although this similarity suggests some functional redundancy between these proteins, an increasing body of evidence supports the existence of isoform-based specificity among RSKs in mediating particular cellular processes. This review briefly presents the similarities between RSK family members before focusing on the specific function of each of the isoforms and their involvement in cancer progression. Cancer Res; 73(17); 1–8. Ó2013 AACR. Introduction subsequently cloned throughout the Metazoan kingdom (2). The extracellular signal–regulated kinase (ERK)1/2 pathway The genomic analysis of several cancer types suggests that fi is involved in key cellular processes, including cell prolifera- these genes are not frequently ampli ed or mutated, with some tion, differentiation, survival, metabolism, and migration. notable exceptions (e.g., in the case of hepatocellular carcino- More than 30% of all human cancers harbor mutations within ma; ref. 6). Table 1 summarizes reported genetic changes in this pathway, mostly resulting in gain of function and conse- RSK genes.
    [Show full text]
  • Control of P70 Ribosomal Protein S6 Kinase and Acetyl‐Coa Carboxylase
    Eur. J. Biochem. 269, 3751–3759 (2002) Ó FEBS 2002 doi:10.1046/j.1432-1033.2002.03074.x Control of p70 ribosomal protein S6 kinase and acetyl-CoA carboxylase by AMP-activated protein kinase and protein phosphatases in isolated hepatocytes Ulrike Krause*, Luc Bertrand and Louis Hue Hormone and Metabolic Research Unit, Christian de Duve International Institute of Cellular and Molecular Pathology and University of Louvain Medical School, Brussels, Belgium Certain amino acids, like glutamine and leucine, induce activation of both ACC and p70S6K was blocked or an anabolic response in liver. They activate p70 riboso- reversed when AMPK was activated. This AMPK acti- mal protein S6 kinase (p70S6K)and acetyl-CoA car- vation increased Ser79 phosphorylation in ACC but boxylase (ACC)involved in protein and fatty acids decreased Thr389 phosphorylation in p70S6K. Protein synthesis, respectively. In contrast, the AMP-activated phosphatase inhibitors prevented p70S6K activation when protein kinase (AMPK), which senses the energy state of added prior to the incubation with amino acids, whereas the cell and becomes activated under metabolic stress, they enhanced p70S6K activation when added after the inactivates by phosphorylation key enzymes in biosyn- preincubation with amino acids. It is concluded that (a) thetic pathways thereby conserving ATP. In this paper, AMPK blocks amino-acid-induced activation of ACC we studied the effect of AMPK activation and of protein and p70S6K, directly by phosphorylating Ser79 in ACC, phosphatase inhibitors, on the amino-acid-induced acti- and indirectly by inhibiting p70S6K phosphorylation, and vation of p70S6K and ACC in hepatocytes in suspension. (b)both activation and inhibition of protein phosphatases AMPK was activated under anoxic conditions or by are involved in the activation of p70S6K by amino acids.
    [Show full text]
  • Combating Resistance to Epidermal Growth Factor Recpetor Inhibitors in Triple Negative Breast Cancer Julie Marie Madden Wayne State University
    Wayne State University Wayne State University Dissertations 1-1-2014 Combating Resistance To Epidermal Growth Factor Recpetor Inhibitors In Triple Negative Breast Cancer Julie Marie Madden Wayne State University, Follow this and additional works at: http://digitalcommons.wayne.edu/oa_dissertations Part of the Cell Biology Commons, and the Oncology Commons Recommended Citation Madden, Julie Marie, "Combating Resistance To Epidermal Growth Factor Recpetor Inhibitors In Triple Negative Breast Cancer" (2014). Wayne State University Dissertations. Paper 1017. This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState. COMBATING RESISTANCE TO EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS IN TRIPLE NEGATIVE BREAST CANCER by JULIE M MADDEN DISSERTATION Submitted to the Graduate School of Wayne State University, Detroit, Michigan in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY 2014 MAJOR: CANCER BIOLOGY Approved by: ______________________________________ Advisor Date ______________________________________ Co-Advisor Date ______________________________________ ______________________________________ ______________________________________ DEDICATION Vires, Fides, Motum Ducit This work is dedicated to my unwavering parents. They never questioned when I wanted to stay in school forever and always encouraged me to follow my dreams no matter where they took me. They were always there to offer support when I decided to fly halfway across the world to study (three times) or travel hundreds of miles to see Oasis in concert or watch Man Utd play. Your trials with cancer led me into this field and your strength through it all drove me to help others fight and survive.
    [Show full text]
  • The Mtor Substrate S6 Kinase 1 (S6K1)
    The Journal of Neuroscience, July 26, 2017 • 37(30):7079–7095 • 7079 Cellular/Molecular The mTOR Substrate S6 Kinase 1 (S6K1) Is a Negative Regulator of Axon Regeneration and a Potential Drug Target for Central Nervous System Injury X Hassan Al-Ali,1,2,3* Ying Ding,5,6* Tatiana Slepak,1* XWei Wu,5 Yan Sun,5,7 Yania Martinez,1 Xiao-Ming Xu,5 Vance P. Lemmon,1,3 and XJohn L. Bixby1,3,4 1Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, Florida 33136, 2Peggy and Harold Katz Family Drug Discovery Center, University of Miami Miller School of Medicine, Miami, Florida 33136, 3Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, Florida 33136, 4Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, Florida 33136, 5Spinal Cord and Brain Injury Research Group, Stark Neurosciences Research Institute, Department of Neurological Surgery, Indiana University School of Medicine, Indianapolis, Indiana 46202, 6Department of Histology and Embryology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China, and 7Department of Anatomy, Histology and Embryology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China Themammaliantargetofrapamycin(mTOR)positivelyregulatesaxongrowthinthemammaliancentralnervoussystem(CNS).Althoughaxon regeneration and functional recovery from CNS injuries are typically limited, knockdown or deletion of PTEN, a negative regulator of mTOR, increases mTOR activity and induces robust axon growth and regeneration. It has been suggested that inhibition of S6 kinase 1 (S6K1, gene symbol: RPS6KB1), a prominent mTOR target, would blunt mTOR’s positive effect on axon growth. In contrast to this expectation, we demon- strate that inhibition of S6K1 in CNS neurons promotes neurite outgrowth in vitro by twofold to threefold.
    [Show full text]
  • The Role of the P90 Ribosomal S6 Kinase Family in Prostate Cancer Progression and Therapy Resistance
    Oncogene (2021) 40:3775–3785 https://doi.org/10.1038/s41388-021-01810-9 REVIEW ARTICLE The role of the p90 ribosomal S6 kinase family in prostate cancer progression and therapy resistance 1 1 1 Ryan Cronin ● Greg N. Brooke ● Filippo Prischi Received: 27 November 2020 / Revised: 8 April 2021 / Accepted: 20 April 2021 / Published online: 10 May 2021 © The Author(s) 2021. This article is published with open access Abstract Prostate cancer (PCa) is the second most commonly occurring cancer in men, with over a million new cases every year worldwide. Tumor growth and disease progression is mainly dependent on the Androgen Receptor (AR), a ligand dependent transcription factor. Standard PCa therapeutic treatments include androgen-deprivation therapy and AR signaling inhibitors. Despite being successful in controlling the disease in the majority of men, the high frequency of disease progression to aggressive and therapy resistant stages (termed castrate resistant prostate cancer) has led to the search for new therapeutic targets. The p90 ribosomal S6 kinase (RSK1-4) family is a group of highly conserved Ser/Thr kinases that holds promise as a novel target. RSKs are effector kinases that lay downstream of the Ras/Raf/MEK/ERK signaling pathway, and aberrant 1234567890();,: 1234567890();,: activation or expression of RSKs has been reported in several malignancies, including PCa. Despite their structural similarities, RSK isoforms have been shown to perform nonredundant functions and target a wide range of substrates involved in regulation of transcription and translation. In this article we review the roles of the RSKs in proliferation and motility, cell cycle control and therapy resistance in PCa, highlighting the possible interplay between RSKs and AR in mediating disease progression.
    [Show full text]
  • Canonical, Non-Canonical and Atypical Pathways of Nuclear Factor Кb Activation in Preeclampsia
    International Journal of Molecular Sciences Article Canonical, Non-Canonical and Atypical Pathways of Nuclear Factor кb Activation in Preeclampsia Agata Sakowicz 1,* , Michalina Bralewska 1 , Tadeusz Pietrucha 1, Dominika E Habrowska-Górczy ´nska 2 , Agnieszka W Piastowska-Ciesielska 2 , Agnieszka Gach 3, Magda Rybak-Krzyszkowska 4 , Piotr J Witas 5, Hubert Huras 4, Mariusz Grzesiak 6,7 and Lidia Biesiada 8 1 Medical University of Lodz, Department of Medical Biotechnology, 90-752 Lodz, Poland; [email protected] (M.B.); [email protected] (T.P.) 2 Medical University of Lodz, Department of Cell Cultures and Genomic Analysis, 90-752 Lodz, Poland; [email protected] (D.E.H.-G.); [email protected] (A.W.P.-C.) 3 Department of Genetics, Polish Mother’s Memorial Hospital-Research Institute in Lodz, 93-338 Lodz, Poland; [email protected] 4 Department of Obstetrics and Perinatology, University Hospital in Krakow, 31-501 Krakow, Poland; [email protected] (M.R.-K.); [email protected] (H.H.) 5 Medical University of Lodz, Department of Haemostatic Disorders, 92-215 Lodz, Poland; [email protected] 6 Department of Perinatology, Obstetrics and Gynecology, Polish Mother’s Memorial Hospital-Research Institute in Lodz, 93-338 Lodz, Poland; [email protected] 7 Medical University of Lodz, Department of Obstetrics and Gynecology, 93-338 Lodz, Poland 8 Department of Obstetrics and Gynecology, Polish Mother’s Memorial Hospital-Research Institute, 93-338 Lodz, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-426-393-180; Fax: +48-426-393-181 Received: 21 June 2020; Accepted: 31 July 2020; Published: 4 August 2020 Abstract: Although higher nuclear factor κB (NFκB) expression and activity is observed in preeclamptic placentas, its mechanism of activation is unknown.
    [Show full text]
  • For a PDK1 Inhibitor, the Substrate Matters Zachary A
    Biochem. J. (2011) 433, e1–e2 (Printed in Great Britain) doi:10.1042/BJ20102038 e1 COMMENTARY For a PDK1 inhibitor, the substrate matters Zachary A. KNIGHT1 The Rockefeller University, 1230 York Avenue, New York, NY 10065, U.S.A. More than 20 protein kinases are directly activated by 3- blocks the phosphorylation of known PDK1 substrates, but phosphoinositide-dependent kinase 1 (PDK1), which is a central surprisingly find that the potency and kinetics of inhibition vary component of the pathways that regulate cell growth, proliferation for different PDK1 targets. This substrate-specific inhibition has and survival. Despite the importance of PDK1 in cell signalling, implications for the development of PDK1 inhibitors as drugs. highly selective PDK1 inhibitors have not been described. In this issue of the Biochemical Journal, Dario Alessi’s group and their Key words: kinase inhibitor, phosphoinositide 3-kinase (PI3K), collaborators at GlaxoSmithKline report GSK2334470, a potent ribosomal S6 kinase (RSK), p70 ribosomal S6 kinase (S6K), and selective PDK1 inhibitor. They show that this compound serum- and glucocorticoid-induced protein kinase (SGK). If the kinome had a social hierarchy, then the AGC family would tool. It is therefore surprising that such compounds have not be the aristocracy. The AGC family is named after its prototypical been described. The only putatively selective PDK1 inhibitors members: protein kinase A, protein kinase G and protein kinase C published to date were a series of aminopyrimidines reported (PKC) [1]. These kinases were the first shown to be regulated by by 2005 [2]. A representative of this class, BX-795, was shown second messengers such as calcium, lipids and cyclic nucleotides.
    [Show full text]